tbuckley/cabot-search huggingface dataset:
Botulinum Toxin Treatment of Spasmodic Torticollis
Authors: T J Anderson, J Rivest, R Stell, M J Steiger, H Cohen, P D Thompson, C D Marsden
Journal: Journal of the Royal Society of Medicine (1992)

We reviewed the efficacy and adverse effects of repeated botulinum toxin injections into hyperactive neck muscles of 107 successive patients with spasmodic torticollis. They received 510 injection treatments over a median period of 15 months (range 3-42 months). One patient failed to benefit at all, but 101 (95%) patients reported considerable (moderate or excellent) benefit from at least one treatment. On a global subjective response rating, 93% of 429 treatments resulted in some improvement and 76% in moderate or excellent improvement. Pain reduction followed 89% of 190 treatments with moderate or excellent reduction after 66%. Median duration of benefit was 9 weeks. All torticollis types responded equally well and injections into two (or more) involved neck muscles were more effective than injection into a single muscle. The most frequent adverse effect was dysphagia, occurring after 44% of all treatments, but this was severe after only 2%. Antibodies to botulinum toxin were detected in the serum of three out of the five patients in whom loss of treatment efficacy occurred. We conclude that botulinum toxin treatment is the most effective available therapy for spasmodic torticollis and practical advice is provided for anyone wishing to set up the technique.
Dissémination d’un clone de SARM hétérorésistant à l’oxacilline aux Pays-Bas
Authors: W J B Wannet
Journal: Eurosurveillance (2002)

Depuis 2001, on a observe aux Pays-Bas une augmentation du nombre de souches de SARM heteroresistantes a l’oxacilline. La dissemination de ces souches peut passer inapercue, leur resistance phenotypique heterogene aux beta-lactamines influant sur les resultats des tests de sensibilite. De ce fait, des analyses complementaires utilisant l’agglutination au latex de la PBP2a ou la PCR sont recommandees.
Virus of Avian Myeloblastosis. XIV. Neoplastic Response of Normal Chicken Bone Marrow Treated with the Virus in Tissue Culture2&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: G. S. Beaudreau, Caroline Becker, R. A. Bonar, A. M. Wallbank, D. Beard, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1960)

Bone marrow of normal chickens, 37 to 168 days of age, was isolated in culture and exposed to avian myeloblastosis virus. After an interval of 12 to 20 days, there was evidence of change in the treated cultures as manifested by multiplication of cells with the characteristics of myeloblasts. With increase in growth of myeloblasts, there was an associated liberation of myeloblastosis virus into the culture fluid. Wide variation was observed in the rates of cell multiplication and viral synthesis from one culture series to another. The level of response could not be related to tissue-culture conditions nor to the age of the donors of the bone marrow. The ultrastructure of the cells was identical with that of myeloblasts from the circulation in culture, showing evidence of the same series of structures related to virus synthesis. Transfer of the cells derived from bone marrow to normal chickens resulted in transmission of the disease.
Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors
Authors: Didier Meulendijks, Ulrik N. Lassen, Lillian L. Siu, Alwin D.R. Huitema, Vaios Karanikas, Morten Mau-Sorensen, Derek J. Jonker, Aaron R. Hansen, Mary E. Simcox, Kathleen J. Schostack, Dean Bottino, Hua Zhong, Markus Roessler, Suzana M. Vega-Harring, Tiantom Jarutat, David Geho, Karen Wang, Mark DeMario, Glenwood D. Goss, Jan H.M. Schellens
Journal: Clinical Cancer Research (2015)

The TWEAK-Fn14 pathway represents a novel anticancer target that is being actively investigated. Understanding the relationship between pharmacokinetics of anti-TWEAK therapeutics and tumor pharmacodynamics is critical. We investigated exposure-response relationships of RG7212, an anti-TWEAK mAb, in patients with Fn14-expressing tumors.Patients with Fn14-positive tumors (IHC ≥ 1+) treated in a phase I first-in-human study with ascending doses of RG7212 were the basis for this analysis. Pharmacokinetics of RG7212 and dynamics of TWEAK were determined, as were changes in tumor TWEAK-Fn14 signaling in paired pre- and posttreatment tumor biopsies. The objectives of the analysis were to define exposure-response relationships and the relationship between pretreatment tumor Fn14 expression and pharmacodynamic effect. Associations between changes in TWEAK-Fn14 signaling and clinical outcome were explored.Thirty-six patients were included in the analysis. RG7212 reduced plasma TWEAK to undetectable levels at all observed RG7212 exposures. In contrast, reductions in tumor Fn14 and TRAF1 protein expression were observed only at higher exposure (≥ 300 mg*h/mL). Significant reductions in tumor Ki-67 expression and early changes in serum concentrations of CCL-2 and MMP-9 were observed exclusively in patients with higher drug exposure who had high pretreatment tumor Fn14 expression. Pretreatment tumor Fn14 expression was not associated with outcome, but a trend toward longer time on study was observed with high versus low RG7212 exposure.RG7212 reduced tumor TWEAK-Fn14 signaling in a systemic exposure-dependent manner. In addition to higher exposure, relatively high Fn14 expression might be required for pharmacodynamic effect of anti-TWEAK monoclonal antibodies.
Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice
Authors: Owen M. Peters, Gabriela Toro Cabrera, Helene Tran, Tania F. Gendron, Jeanne E. McKeon, Jake Metterville, Alexandra Weiss, Nicholas Wightman, Johnny Salameh, Juhyun Kim, Huaming Sun, Kevin B. Boylan, Dennis Dickson, Zachary Kennedy, Ziqiang Lin, Yong-Jie Zhang, Lillian Daughrity, Chris Jung, Fen-Biao Gao, Peter C. Sapp, H. Robert Horvitz, Daryl A. Bosco, Solange P. Brown, Pieter de Jong, Leonard Petrucelli, Christian Mueller, Robert H. Brown
Journal: Neuron (2015)
Remember what I told you about therapeutic arteriogenesis, 11 years ago?: EXPERT'S PERSPECTIVE
Authors: M. J. Post
Journal: Cardiovascular Research (2012)

This editorial refers to an article by I.E. Hoefer et al .[1][1] published in Cardiovascular Research in 2001. It is accompanied by a retrospective editorial by two authors of that original article, I.E. Hoefer and W. Schaper, pp. 154–156, this issue, as part of this Spotlight on Landmark Papers in Cardiovascular Research . 

‘It remains to be demonstrated if the gain in time is of sufficient relevance in a clinical setting where often the time of occlusion is either not known or has occurred some time ago.’ With this insightful remark, the paper by Hoefer et al .1 ends after it had unequivocally demonstrated that there is only a short-time window for pro-arteriogenic therapy such as MCP-1 to establish its efficacy.

Onward from the early 1970s, the Schaper group has worked and published >80 papers on the molecular mechanisms underlying collateral formation and can without doubt be considered the single most influential authority on collateral formation. In addition, numerous trainees of the laboratory have spread out and continued academic arteriogenesis research as group …

 [1]: #ref-1
Beta 2-microglobulin-dependent NK1.1+ T cells are not essential for T helper cell 2 immune responses.
Authors: D R Brown, D J Fowell, D B Corry, T A Wynn, N H Moskowitz, A W Cheever, R M Locksley, S L Reiner
Journal: The Journal of Experimental Medicine (1996)

A number of investigations have established the critical role of interleukin 4 (IL-4) in mediating the development of T helper (Th)2 effector cells in vitro and in vivo. Despite intensive study, the origin of the IL-4 required for Th2 priming and differentiation remains unclear. Natural killer (NK)1.1+ alpha/beta T cell receptor+ T(NT) cells, a unique lineage of cells capable of producing large amounts of IL-4 after activation in vivo, are important candidates for directing Th2 priming. These cells are selected by the nonpolymorphic major histocompatibility complex (MHC) class I molecule, CD1, and are deficient in beta 2-microglobulin (beta 2m)-null mice. We used beta 2m-deficient mice on both BALB/c and C57BL/6 backgrounds to examine their capacity to mount Th2 immune responses after challenge with a number of well-characterized antigens administered by a variety of routes. As assessed by immunization with protein antigen, infection with Leishmania major, embolization with eggs of Schistosoma mansoni, intestinal infection with Nippostrongylus brasiliensis, or induction of airway hyperreactivity to aerosolized antigen, beta 2m-deficient mice developed functional type 2 immune responses that were not substantially different than those in wild-type mice. Production of IL-4 and the generation of immunoglobulin E (IgE) and eosinophil responses were preserved as assessed by a variety of assays. Collectively, these results present a comprehensive analysis of type 2 immune responses in beta 2m-deficient mice, and indicate that beta 2m-dependent NT cells are not required for Th2 development in vivo.
Efficacy and safety of continuous sedation for agitated patients under noninvasive ventilation
Authors: Takeshi Matsumoto, Takahisa Kawamura, Koji Tamai, Junpei Takeshita, Kosuke Tanaka, Kazuya Monden, Kazuma Nagata, Kyoko Otsuka, Atsushi Nakagawa, Ryo Tachikawa, Kojiro Otsuka, Keisuke Tomii
Journal: European Respiratory Journal (2012)

Introduction:  Sedation is often required for agitated patients under noninvasive ventilation (NIV). However, there have been few reports on use of continuous sedation in these patients.   Aims:  To evaluate the efficacy and safety of continuous sedation for agitated patients under NIV.   Methods:  We retrospectively reviewed 110 patients receiving NIV for acute respiratory failure from May 2007 to December 2011, who needed sedation for treatment of agitation. Difference in clinical outcomes was compared between continuous use group and intermittent use group, according to do-not-intubate (DNI) status (n=73) or non-DNI status (n=37).   Results:  In non-DNI patients, the severity assessed by baseline P/F ratio and mortality were similar between continuous use group (n=10) and intermittent use group (n=27) (117±66 mmHg vs. 116±50 mmHg, p=0.95 and 10% vs. 22%, p=0.40). No patient in continuous use group required intubation due to agitation, while three patients in intermittent use group required intubation due to failure of sedation (0% vs. 11%, p=0.54). In DNI patients, baseline P/F ratio was lower and the mortality was higher in continuous use group (n=33) compared with intermittent use group (n=40) (113±51 mmHg vs. 151±82 mmHg, p=0.017, and 85% vs. 58%, p=0.011). Only one patient in continuous use group failed to continue NIV due to agitation. Patients with continuous sedation were safely managed under NIV with the level of sedation assessed by Richmond Agitation Sedation Scale, except only one adverse event of hypotension caused by midazolam.   Conclusions:  Continuous sedation could be safely administered, and potentially prevent undesirable intubation due to persisting agitation under NIV.
Interactive and Mediational Etiologic Models of Eating Disorder Onset: Evidence from Prospective Studies
Authors: Eric Stice
Journal: Annual Review of Clinical Psychology (2015)

It is vital to elucidate how risk factors work together to predict eating disorder onset because it should improve the yield of prevention efforts. Risk factors that have predicted eating disorder onset in multiple studies include low body mass index (BMI) for anorexia nervosa; thin-ideal internalization, perceived pressure to be thin, body dissatisfaction, dieting, and negative affect for bulimia nervosa; and body dissatisfaction and dieting for purging disorder. No such risk factors have been identified for binge eating disorder. Classification tree analyses have identified several amplifying interactions, mitigating interactions, and alternative pathway interactions between risk factors, such as evidence that elevated BMI amplifies the risk between appearance overvaluation and the future onset of recurrent binge eating. However, there have been no tests of mediational risk factor models in the prediction of eating disorder onset. Gaps in the literature are identified and procedures for providing rigorous tests of interactive and mediational etiologic models are outlined.
Long-Term Outcome of Dasatinib First-Line Treatment in Gastrointestinal Stromal Tumors: a Multicenter Two Stage Phase Ii Trial Sakk 56/07
Authors: M. Montemurro, A. Cioffi, J. Domont, P. Rutkowski, A.D. Roth, R. von Moos, R. Inauen, B. Bui, R.O. Burkhard, C. Knuesli, S. Bauer, P. Cassier, H. Schwarb, A. Le Cesne, D. Koeberle, D. Baertschi, D. Dietrich, C. Biaggi, J. Prior, S. Leyvraz
Journal: Annals of Oncology (2014)
Extracellular matrix component mRNA expression in glomeruli in experimental focal glomerulosclerosis.
Authors: I Ebihara, S Suzuki, T Nakamura, M Fukui, Y Yaguchi, Y Tomino, H Koide
Journal: Journal of the American Society of Nephrology (1993)

This study was designed to assess how the expression of genes for components of the extracellular matrix is altered in a model of focal glomerular sclerosis. In this model, a unilateral nephrectomy combined with injections of puromycin aminonucleoside induces a much higher incidence of focal glomerular sclerosis. Rats received puromycin aminonucleoside on days 0, 27, 34, and 41 and underwent unilateral nephrectomy on day 22. Control rats received physiologic saline injections with and without unilateral nephrectomy. Rats from each group were killed on days 48, 60, and 80. The steady-state levels of glomerular mRNA encoding type IV collagen, the B1 and B2 chains of laminin, heparan sulfate proteoglycan, and type I and type III collagens were compared in both the puromycin aminonucleoside-treated and the control glomeruli. The mRNA levels encoding type IV collagen and laminin B1 and B2 were increased three-, two-, and twofold, respectively, on day 48 of focal glomerular sclerosis. These transcripts were further increased eight-, seven-, and eightfold, respectively, on day 80 compared with the control glomeruli (P < 0.01). In contrast, heparan sulfate proteoglycan mRNA levels were not increased on day 48 when the animals had marked proteinuria. However, the heparan sulfate proteoglycan mRNA levels did become elevated by day 60 and remained elevated thereafter. The expression of type I and type III collagen mRNA was increased 12- and 7-fold, respectively (P < 0.01), on day 80 in focal glomerular sclerosis rats compared with the controls. An immunofluorescence study revealed the accumulation of immunoglobulin M, C3, type IV collagen, laminin, heparan sulfate proteoglycan, and type I and type III collagens in the sclerotic area. These data indicate that changes in the mRNA levels for components of the basement membrane and interstitial collagen are associated with the development of glomerular sclerosis.
SLCO1B1 variants and enalapril-induced cough: a pharmacogenetics study in China
Authors: Jian-Quan Luo, Ning-Ling Sun, Fa-Zhong He, Lu-Yan Wang, Gen-Fu Tang, Qing Li, Xiao-Ping Chen, Zhao-Qian Liu, Hong-Hao Zhou, Wei Zhang
Journal: The Lancet (2015)
Idraparinux versus Standard Therapy for Venous Thromboembolic Disease
Authors: Harry R Buller, Ander T Cohen, Bruce Davidson, Hervé Decousus, Alex S Gallus, Michael Gent, Gerard Pillion, Franco Piovella, Martin H Prins, Gary E Raskob
Journal: New England Journal of Medicine (2007)

Venous thromboembolism is treated with unfractionated heparin or low-molecular-weight heparin, followed by a vitamin K antagonist. We investigated the potential use of idraparinux, a long-acting inhibitor of activated factor X, as a substitute for standard therapy.
Successful use of cuffed central venous hemodialysis catheters inserted percutaneously.
Authors: R D Swartz, J M Messana, C J Boyer, N M Lunde, W F Weitzel, T L Hartman
Journal: Journal of the American Society of Nephrology (1994)

Although endogenous fistulae and grafts are preferred for permanent hemodialysis access, central venous catheters are often required for varying intervals when creating permanent access is not feasible. The prospective experience with 118 catheters in over a 3.5-yr period is reported; 93 (79%) were placed by percutaneous techniques, and 25 (21%) were placed by operative techniques. Seventy seven catheters (65%) were placed in the subclavian vein, 36 (31%) were placed in the internal jugular vein (usually right side), and 5 (4%) were placed in the femoral vein. Early postplacement complications were infrequent. Catheter function at last local follow-up ranged from several days to nearly 2 yr, averaging approximately 3 mo, even though many patients returned to their referring centers with a functioning catheter after only a short follow-up. Actuarial survival for percutaneously placed catheters was approximately 60% at 6 mo and 30% at 12 mo. Catheter failure occurred in 36% of cases, equally divided between malfunction (thrombosis refractory to fibrinolysis, extrusion, kinking, or related event) and infection with septicemia requiring removal. Such failure was not more frequent after percutaneous placement than after operative placement. Failure due to mechanical malfunction, but not that due to infection, tended to be less frequent among catheters placed in the internal jugular vein than among catheters placed in the subclavian vein. Finally, infection with septicemia involved 22% of all catheters and occurred at an average cumulated rate of approximately one infection per patient-year. Coagulase-positive staphylococcus was the most common organism isolated.(ABSTRACT TRUNCATED AT 250 WORDS)
Restriction-map variation at the zeste-tko region in natural populations of Drosophila melanogaster.
Authors: M Aguadé, N Miyashita, C H Langley
Journal: Molecular Biology and Evolution (1989)

Restriction-map variation in 64 X chromosome lines extracted from three different natural populations of Drosophila melanogaster was investigated with seven six-nucleotide-recognizing enzymes for a 20-kb region including the zeste and tko genes. Ten restriction-site and four length polymorphisms (two insertions and two deletions) were detected. Contrary to the predicted lower level of variation for genes on the X chromosome, the level of variation attributable to nucleotide substitution (estimated heterozygosity/nucleotide = 0.004) was similar to that previously reported for autosomal loci. The amount of insertion/deletion variation in the studied region was within the range observed in autosomal regions and thus not explainable by a simple selection model against the effects of insertional mutations. A general lack of linkage disequilibrium between polymorphic sites was observed.
In the name of ventilator-associated pneumonia prevention: lung microbiota blown away by colistin!
Authors: Saad Nseir, Ignacio Martin-Loeches
Journal: European Respiratory Journal (2015)

Negative RCT results and harmful effects on lung microbiota mean inhaled antimicrobials cannot be used to prevent VAP <http://ow.ly/T1kZS> Whilst ventilator-associated pneumonia (VAP) incidence has decreased during the last decade [1], this infection is still associated with increased duration of mechanical ventilation [2], high mortality rates and additional cost [3]. As VAP incidence is considered as an indicator of quality of care provided to the critically ill patient, preventing this infection has become a major public health issue in the intensive care unit (ICU) [4]. After several years of debate on the best diagnosis method for VAP, and in the absence of new therapeutic options, research has moved towards better understanding of pathophysiology of VAP in order to improve preventive strategies [5].
Cost Effectiveness Analysis of Everolimus Plus Exemestane Vs. Bevacizumab Plus Paclitaxel and Bevacizumab Plus Capecitabine for the Management of Postmenopausal Women with Er+ Breast Cancer
Authors: G. Kourlaba, V. Rapti, A. Alexopoulos, J. Relakis, G. Koumakis, M. Chatzikou, N. Maniadakis, V. Georgoulias
Journal: Annals of Oncology (2014)
NM-3, a novel angiogenesis inhibitor, inhibits proliferation of rat 9L glioma cells
Authors: Naoki Agata, Minying Pu, Steven Weitman, Surender Kharbanda
Journal: Cancer Research (2004)

4099   Angiogenesis is functionally defined as the sprouting of new blood vessels from pre-existing vasculature and consists of several distinct stages including endothelial cell proliferation, migration, invasion, and differentiation into new blood vessels. This process is essential for tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is a major angiogenic agent that regulates key steps of the angiogenesis process. Recent studies have reported that NSC 680410, an adamantyl congener of AG957 (NSC 680705) inhibits VEGF secretion and leukemic cell growth in sub-micromolar concentrations. Here, we describe the anti-proliferative, pro-apoptotic and anti-angiogenic activities of Adaphostin, (NSC 680410), and its water-soluble analog NSC 726814. Results from our laboratory indicate that Adaphostin (NSC 680410) is 3-7 fold more potent than its water-soluble analog NSC726814 in inhibiting endothelial cell growth, tube formation and VEGF induced migration. Adaphostin induces apoptosis in HUVEC at concentrations and exposure times at which the cells are refractory to NSC 726814. Since VEGF is essential for vasculogenesis and angiogenesis, we investigated the effect of adaphostin and NSC 726814 on VEGF secretion in endothelial cells. Unlike leukemia cells (where Adaphostin caused a decrease in VEGF levels), Adaphostin caused a marked increase (30-fold) in VEGF secretion into the media compared to untreated control or NSC726814 treated cells. This increase could be due to oxidative stress in the treated endothelial cells and needs further investigation. These findings suggest that Adaphostin (NSC 680410) is a potent anti-angiogenic inhibitor and may provide a means for therapeutic intervention in metastatic disease. These observations should aid in the design of future clinical trials of this novel agent.
Adjuvant Oxaliplatin Dose and Dose Reductions are Associated with Severity of Peripheral Neuropathy Among Colorectal Cancer Survivors: Results from the Population-Based Profiles Registry
Authors: T. Beijers, F. Mols, V.C. Tjan-Heijnen, C.G. Faber, L.V. van de Poll-Franse, G. Vreugdenhil
Journal: Annals of Oncology (2014)
Phase 1 Experience of Tivantinib in Patients with Hepatocellular Carcinoma (HCC) or Biliary Tract Cancer (BTC)
Authors: F. Chai, G. Abbadessa, R. Savage, H. Zahir, Y. Chen, M. Lamar, J. Kazakin, D. Ferrari, R. von Roemeling, B. Schwartz
Journal: Annals of Oncology (2012)